Maintenance chemotherapy in the management of epithelial ovarian cancer.
Markman M.
Cancer Metastasis Rev · review; journal article · DOI 10.1007/s10555-014-9537-x PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för olaparib. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
22 hitsPhase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer.
Bendell J, O'Reilly EM, Middleton MR, Chau I, Hochster H, Fielding A, Burke W, Burris H.
Ann Oncol · comparative study; research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1093/annonc/mdu581PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma.
Karpel-Massler G, Pareja F, Aimé P, Shu C, Chau L, Westhoff MA, Halatsch ME, Crary JF, Canoll P, Siegelin MD.
PLoS One · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1371/journal.pone.0114583BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib.
Faraoni I, Compagnone M, Lavorgna S, Angelini DF, Cencioni MT, Piras E, Panetta P, Ottone T, Dolci S, Venditti A, Graziani G, Lo-Coco F.
Biochim Biophys Acta · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbadis.2014.12.001PARP inhibitor, olaparib ameliorates acute lung and kidney injury upon intratracheal administration of LPS in mice.
Kapoor K, Singla E, Sahu B, Naura AS.
Mol Cell Biochem · research support, non-u.s. gov't; journal article · DOI 10.1007/s11010-014-2271-4Gemtuzumab ozogamicin and olaparib exert synergistic cytotoxicity in CD33-positive HL-60 myeloid leukemia cells.
Yamauchi T, Uzui K, Nishi R, Shigemi H, Ueda T.
Anticancer Res · research support, non-u.s. gov't; journal articleCombination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, Luo W, Quy P, Whalen C, Obermayer L, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis UA.
Lancet Oncol · clinical trial, phase ii; research support, n.i.h., intramural; comparative study; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.1016/s1470-2045(14)70391-2PARP inhibitor olaparib increases the oncolytic activity of dl922-947 in in vitro and in vivo model of anaplastic thyroid carcinoma.
Passaro C, Volpe M, Botta G, Scamardella E, Perruolo G, Gillespie D, Libertini S, Portella G.
Mol Oncol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1016/j.molonc.2014.07.022Poly (ADP-ribose) polymerase inhibition synergizes with the NF-κB inhibitor DHMEQ to kill hepatocellular carcinoma cells.
Lampiasi N, Umezawa K, Montalto G, Cervello M.
Biochim Biophys Acta · journal article · DOI 10.1016/j.bbamcr.2014.07.010Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours.
Del Conte G, Sessa C, von Moos R, Viganò L, Digena T, Locatelli A, Gallerani E, Fasolo A, Tessari A, Cathomas R, Gianni L.
Br J Cancer · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1038/bjc.2014.345Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.
Balmaña J, Tung NM, Isakoff SJ, Graña B, Ryan PD, Saura C, Lowe ES, Frewer P, Winer E, Baselga J, Garber JE.
Ann Oncol · research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1093/annonc/mdu187The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice.
To C, Kim EH, Royce DB, Williams CR, Collins RM, Risingsong R, Sporn MB, Liby KT.
Cancer Prev Res (Phila) · research support, non-u.s. gov't; research-article; journal article · DOI 10.1158/1940-6207.capr-14-0047PARP Inhibitors as P-glyoprotein Substrates.
Lawlor D, Martin P, Busschots S, Thery J, O'Leary JJ, Hennessy BT, Stordal B.
J Pharm Sci · research support, non-u.s. gov't; journal article · DOI 10.1002/jps.23952New insights into PARP inhibitors' effect on cell cycle and homology-directed DNA damage repair.
Jelinic P, Levine DA.
Mol Cancer Ther · research support, non-u.s. gov't; journal article · DOI 10.1158/1535-7163.mct-13-0906-tPARP inhibitor reduces proliferation and increases apoptosis in breast cancer cells.
Shi Y, Zhou F, Jiang F, Lu H, Wang J, Cheng C.
Chin J Cancer Res · research-article; journal article · DOI 10.3978/j.issn.1000-9604.2014.02.13Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
Konstantinopoulos PA, Wilson AJ, Saskowski J, Wass E, Khabele D.
Gynecol Oncol · research-article; journal article · DOI 10.1016/j.ygyno.2014.03.007The use of Olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.
Tahara M, Inoue T, Sato F, Miyakura Y, Horie H, Yasuda Y, Fujii H, Kotake K, Sugano K.
Mol Cancer Ther · research support, non-u.s. gov't; journal article · DOI 10.1158/1535-7163.mct-13-0683Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer.
Chen S, Wang G, Niu X, Zhao J, Tan W, Wang H, Zhao L, Ge Y.
Cancer Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.canlet.2014.02.010Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
Murai J, Huang SY, Renaud A, Zhang Y, Ji J, Takeda S, Morris J, Teicher B, Doroshow JH, Pommier Y.
Mol Cancer Ther · research support, n.i.h., intramural; comparative study; research support, non-u.s. gov't; research-article; journal article · DOI 10.1158/1535-7163.mct-13-0803Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors.
Norris RE, Adamson PC, Nguyen VT, Fox E.
Pediatr Blood Cancer · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1002/pbc.24697Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.
Shimo T, Kurebayashi J, Kanomata N, Yamashita T, Kozuka Y, Moriya T, Sonoo H.
Breast Cancer · research support, non-u.s. gov't; journal article · DOI 10.1007/s12282-012-0356-z4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.
Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, Dillon KJ, Drzewiecki J, Garman S, Gomez S, Javaid H, Kerrigan F, Knights C, Lau A, Loh VM, Matthews IT, Moore S, O'Connor MJ, Smith GC, Martin NM.
J Med Chem · journal article · DOI 10.1021/jm8001263